Specialized Model Services

Joinn Labs focuses on three specialized areas: botulinum toxin efficacy testing, androgenetic alopecia and tumor xenograft/allograft models. We establish standardized, high-fidelity model systems and overcome key technical bottlenecks. Led by PhD-level experts with dedicated testing platforms, we provide end-to-end pharmacodynamic evaluation and mechanistic studies to support IND applications for specialty therapeutics and demonstrate core technical competitiveness.

Joinn Labs addresses key technical challenges for botulinum toxin testing and establishes standardized models using internationally accepted endpoints including LD50 and DAS scoring. Assays are performed by specialized teams; generated data directly supports IND applications for botulinum toxin products and demonstrates leading industry capabilities.

Botulinum toxin efficacy testing demands highly stable models and precise readouts, which directly determine safety and efficacy assessment for drug development. Leveraging extensive experience in neuropharmacology, Joinn Labs overcomes technical hurdles and develops standardized botulinum toxin testing platforms using globally recognized endpoints: LD50 assay, DAS scoring and compound muscle action potential (CMAP) recording. Our assays enable comprehensive and precise measurement of toxin potency, duration of action and safety profiles. Studies are conducted in rats and mice by specialized technical staff to guarantee accuracy, reproducibility and traceability, generating IND-ready data and highlighting our strengths in neuropharmacology and toxin pharmacodynamic evaluation.

Joinn Labs optimizes testosterone propionate induction protocols to build high-fidelity androgenetic alopecia models that recapitulate human pathological features. Supported by specialized hair analysis technology and dermatology pharmacology experts, we deliver pharmacodynamic and mechanistic studies to facilitate the development of hair regenerative therapeutics.

Androgenetic alopecia is highly prevalent clinically with complex pathogenesis. Model specificity and stability are critical to reliable drug evaluation. To support anti-alopecia drug development, Joinn Labs optimizes testosterone propionate induction to establish standardized, reproducible high-fidelity androgenetic alopecia models recapitulating hallmark pathology including follicular atrophy and hair thinning. Using quantitative hair morphology analysis and follicular histopathology, we evaluate candidate drugs for hair regeneration, follicle protection and hormone regulation while investigating mechanisms of action. All models are established by experienced technicians and adaptable to diverse therapeutic candidates, demonstrating our professional advantages in dermatology and hair pharmacology.

Joinn Labs establishes a broad portfolio of syngeneic and xenogeneic tumor transplantation models covering multiple cancer types, optimized by PhD tumor pharmacology experts. Our models closely resemble human malignancies. Supported by advanced instruments including in vivo imaging systems, we provide full-service testing with data directly applicable for global IND applications.

A major challenge in oncology drug development lies in translational similarity between animal tumor models and human cancers. Drawing on years of experience in tumor pharmacology, Joinn Labs establishes a comprehensive library of syngeneic and xenograft tumor models covering lung cancer, breast cancer, melanoma, colorectal cancer, pancreatic cancer and other prevalent malignancies. We employ internationally recognized tumor cell lines and animal strains following GLP-compliant protocols. All models are optimized by international PhD-level oncology pharmacologists to recapitulate growth patterns, pathology, progression and metastasis of human tumors. Supported by in vivo imaging systems and flow cytometry, we comprehensively assess tumor growth inhibition, anti-metastatic activity and immunomodulatory effects of test articles and investigate mechanisms of action, delivering precise and reliable preclinical support and demonstrating our core strengths in oncology model development and pharmacodynamic evaluation.

Syngeneic tumor models are established in immunocompetent animals with identical genetic background, preserving intact host immune systems to recapitulate tumor microenvironment and anti-tumor immune responses. They represent core models for immuno-oncology and targeted therapy evaluation. Joinn Labs offers syngeneic models for multiple common cancer types using matched mouse strains with model establishment success rate exceeding 98%, featuring excellent stability and reproducibility. Our technical team continuously monitors tumor progression and provides full support including tumor volume measurement, TGI calculation and immune biomarker detection to satisfy all testing requirements for immuno-oncology programs. All data supports IND applications.

Xenograft models employ immunodeficient mice as recipients for human tumor cells, faithfully recapitulating growth profiles and pathological features of human cancers. They serve as core models for testing targeted therapeutics and chemotherapeutics. Joinn Labs uses internationally recognized immunodeficient strains including BALB/c nude, NOG and NPG to establish xenograft models for pancreatic cancer, liver cancer, lung cancer, breast cancer and other prevalent malignancies using standard human tumor cell lines. Model establishment success rate exceeds 97%. Supported by in vivo imaging and tumor histopathology, we fully evaluate anti-tumor efficacy, target specificity and safety profiles of candidate drugs and investigate mechanisms of action. Data can be used for global IND filings, demonstrating our capabilities in human tumor model development.